ClinicalTrialsFinder
RecruitingNCT05100056

A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Effectiveness and Safety of Consolidative Brentuximab Vedotin (BV) Treatment Administered to Hodgkin's Lymphoma (HL) Patients That Had Undergone Autologous Stem Cell Transplant (ASCT). Prospective, Multicenter, Observational Study

Sponsor

Takeda

Enrollment

70 participants

Start Date

Mar 8, 2022

Study Type

OBSERVATIONAL

Conditions

Hodgkin Lymphoma

Summary

The main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks. When study treatment has completed, a follow-up visit will be scheduled every 3 months during the first year and every 4-6 months during the next year.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting real-world information on how brentuximab vedotin (Adcetris) is working in adults with Hodgkin's lymphoma who have had or are candidates for a stem cell transplant, outside of a standard clinical trial setting. **You may be eligible if...** - You are an adult (18 years or older) with Hodgkin's lymphoma - You have undergone or are a candidate for an autologous stem cell transplant - You are being treated with brentuximab vedotin as part of standard care - You were enrolled in the related treatment program (BV HL NDP) **You may NOT be eligible if...** - You are currently participating in or planning to join another interventional clinical trial - Your doctor does not consider you suitable to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo Intervention

This is a non-interventional study.

Locations(13)

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

Wroclaw, Dolnoslskie, Poland

Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu

Poznan, Greater Poland Voivodeship, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial w Krakowie

Krakow, Lesser Poland Voivodeship, Poland

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

Krakow, Lesser Poland Voivodeship, Poland

Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli

Lublin, Lublin Voivodeship, Poland

NU-MED Specjalistyczny Szpital Onkologiczny Tomaszow Mazowiecki

Tomaszow Mazowiecki, Masovian Voivodeship, Poland

Uniwersyteckie Centrum Kliniczne WUM

Warsaw, Masovian Voivodeship, Poland

Instytut Hematologii i Transfuzjologii

Warsaw, Masovian Voivodeship, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Warsaw, Masovian Voivodeship, Poland

Uniwersyteckie Centrum Kliniczne, Gdansk

Gdansk, Pomeranian Voivodeship, Poland

Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slskiego Uniwersytetu Medycznego w Katowicach

Katowice, Slskie, Poland

Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warminsko - Mazurskim Centrum Onkologii w Olsztynie

Olsztyn, Warmian-Masurian Voivodeship, Poland

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii, im. M. Kopernika w Lodzi

Lodz, Łódź Voivodeship, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05100056

Related Trials

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT050924511 location

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

NCT06002828428 locations

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

NCT075663777 locations

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

NCT068128584 locations

Methods of T Cell Depletion Trial (MoTD)

NCT0488874117 locations